title: Radioiodine treatment in autoimmune hyperthyroidism: analysis of outcomes in relation to dosage.
abstract: BACKGROUND
  Controversy exists regarding the optimal dose of radioiodine ((131)I) therapy in autoimmune hyperthyroidism (i.e., Graves' Disease).
  
  
  METHODS
  In order to evaluate the efficacy and safety of high dose (131)I therapy in autoimmune hyperthyroidism, a retrospective review of patients who received (131)I therapy for Graves' disease from 1980 to 2000 in the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City was carried out.
  
  
  RESULTS
  The study population consisted of 596 autoimmune hyperthyroid patients with a mean age of 35 years. The mean follow-up period was 10.31 +/- 2.37 years. Remission of hyperthyroidism occurred in 81.9%, persistent hyperthyroidism was recorded in 14.4% and recurrence in 3.7%. (131)I doses of 5-9 mCi (185-333 MBq) and > or =20 mCi (> or =740 MBq) were associated with remission rates of 65.5% and 87.7% respectively. Remission occurred earlier and more often with high doses of (131)I. The high-dose group (20-30 mCi [740-1110 MBq]) had the lowest rate of persistence (9.7, 27.5 and 34.3%, for 20-30 [740-1110 MBq], 10-14 [370-518 MBq] and 5-9 [185-333 MBq] mCi, respectively p <0.05) and hypothyroidism occurred earlier in this group (p = 0.05).
  
  
  CONCLUSIONS
  Remission of autoimmune hyperthyroidism is more likely with doses of 20-30 mCi (740-1110 MBq).
authors.affiliation: Departamento de Endocrinología y Metabolismo, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. sergiohdzj@hotmail.com
authors.forename: Sergio
authors.initials: S
authors.lastname: Hernández-Jiménez
authors.forename: Alvaro
authors.initials: A
authors.lastname: Pachón-Burgos
authors.forename: Carlos Alberto
authors.initials: CA
authors.lastname: Aguilar-Salinas
authors.forename: Víctor
authors.initials: V
authors.lastname: Andrade
authors.forename: Ricardo
authors.initials: R
authors.lastname: Reynoso
authors.forename: Aurelio
authors.initials: A
authors.lastname: Ríos
authors.forename: Alfredo Adolfo
authors.initials: AA
authors.lastname: Reza-Albarrán
authors.forename: Roopa
authors.initials: R
authors.lastname: Mehta
authors.forename: Ofelia
authors.initials: O
authors.lastname: González-Treviño
authors.forename: Francisco Javier
authors.initials: FJ
authors.lastname: Gómez-Pérez
authors.forename: Bernardo
authors.initials: B
authors.lastname: Pérez-Enríquezi
authors.forename: Juan A
authors.initials: JA
authors.lastname: Rull
mesh_terms: D000328:Adult; D001327:Autoimmune Diseases / Q000532:radiotherapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D049970:Graves Ophthalmopathy / Q000532:radiotherapy*; D006801:Humans; D006980:Hyperthyroidism / Q000532:radiotherapy*; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D011867:Radioisotope Teletherapy; D016896:Treatment Outcome
chemical_list: D007457:Iodine Radioisotopes